Labiotech.eu

News and Trends 27 Oct 2015

Belgian Biotech Seed Investment to Produce Affordable Vaccines for Developing Countries

The Belgian biomanufacturing company Univercells and the Japanese pharmaceutical company Takeda have signed a strategic partnership agreement. Univercells has closed a €3M equity investment with Takeda Ventures to produce affordable vaccines. Univercells provides single-use cost-efficient bioprocess solutions to lead the next generation in biomanufacturing. Under the terms of the agreement, the two biotechs will launch a […]

October 27, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 27 Oct 2015

Meet the French Woman who started a Biotech to Save her Daughter from a Rare Disease

Karen Aiach had no background in science or the biotech industry, yet when her daughter Ornella was diagnosed with the super-rare Sanfilippo syndrome this inspired her to co-found and become the CEO of Lysogene, today a clinical-stage biotech based in Paris, France. Now Ornella is participating in the ongoing clinical trials for a new gene […]

October 27, 2015 - 7 minutesmins - By Dani Bancroft

News and Trends 26 Oct 2015

Wow, Europe’s leading CRISPR Biotech signs monster €2.29 Billion Deal

CRIPSR’s hype is not going down yet. CRIPSR/Cas9 or Cpf1 is a revolutionising gene editing tool, which almost won the Nobel Prize of this year (it won nearly all the other biology prizes already). It also caught great interest from the industry and venture capitalists. The leading Biotechs includes: Editas, Boston-based and clozed a $120M found […]

October 26, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 26 Oct 2015

Dementia could bankrupt us all… The Biotech ‘A’ Team comes to the rescue!

The fight against Alzheimer‘s with the World Health Organization and the G8 Dementia Summit rallies a collective of biotech industry specialists also wanting in on the battle front. The latest development in the Dementia Discovery Fund (DDF) includes US Biogen‘s dramatic cuts to redirect $250M into the Neurodegenerative disease venture, and investment into $100M ‘A’ […]

October 26, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Oct 2015

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Amgen is now months away from a European approval with Imlygic (also known as T-VEC) – the first oncolytic immunotherapy for advanced melanoma. The Committee for Medicinal Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMA), have reacted positively. Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, […]

October 26, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 26 Oct 2015

Financial Storm approaching? EU Biotechs start postponing their IPOs in London …

Biotech financing beats record over record since beginning of 2014. Financing has never been as high in Europe (though of course, we know this has always been the case for the US). Just look at Neil Woodford, famous british investor who raised €1.1Bn for its fund and injected it in many companies like Immuncore (2nd biggest VC round […]

October 26, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 24 Oct 2015

What Happened this Week? Ultimate Cancer Review, Biofuels, Microalgae

Monday: Monster €167M NASDAQ-IPO coming for Swiss Antibiotic Biotech Basilea Tuesday: The Ultimate Review on how Biotech Changed Cancer Treatment Wednesday: “CAR-T / TCR Deserves to have a lot of Money because the Data is Very Exciting” Thursday: Aquanos Algae: Israeli Start-up fixes the Global Sustainability issue in Recycling Sewage Water Friday: #Sorry: The World-leading Oncology Company […]

October 24, 2015 - 1 minutemin - By Philip Hemme

News and Trends 23 Oct 2015

#Sorry: The World-leading Oncology Company fails in Phase III

Antibody Drug Conjugate is a smart way to improve chemotherapy. That is the strategy of Roche / Immunogen‘s drug Kadcyla®, which has just failed in Phase III clinical trial to extend its indications. Here are the facts… Antibody Drug Conjugate is at the boundary between chemical and biological drug. The principle is pretty simple; once the antibody fixes to […]

October 23, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 23 Oct 2015

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Novartis, the Swiss Biotech giant, has once again broadened its Immuno-oncology portfolio with the acquisition of US Admune Therapeutics (MA) and forming marketing, commercialization and development partnerships with California’s Xoma and Palobiopharma in Barcelona (Spain). Novartis is a Basel giant in the biotech industry, with their research development programs spanning a broad range of fields […]

October 23, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 23 Oct 2015

Biotech of the week: Genenta Biosciences, a Novel Gene Therapies from Italy

This week we depart from East Germany and head south, through both Liechtenstein and Switzerland to the northern region of Italy, Lombardy. Here we arrive in Italy’s second largest city, Milan. This city is the center of fashion, Italian cuisine and is home to Da Vinci’s, ‘The Last Supper’ however, it is also home […]

October 23, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 22 Oct 2015

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

ArGEN-X from Ghent (BE) and Breda (NL) has initiated its phase I human trials for Auto-immune diseases such as systemic lupus erythmatosus (SLE) – a rare chronic disease which has had little progress in the last 50 years. Here is the story behind SLE… As a rare disease, Dr. House and his fictional diagnostics team […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 22 Oct 2015

This €200M French Biotech uses Red blood Cells to Fight Leukemia & Pancreatic Cancer

Lyon’s Erytech (France) is a clinical biopharma working on improving its red blood cell transported drug, targeting cancers such as acute lymphocytic leukemia (ALL) and pancreatic adenocarcinoma. Now phase I/II trials for its GRASPA therapy have demonstrated good efficacy and safety. Circulating asparagine is needed by cancer cells to grow and proliferate. Erytech’s platform uses […]

October 22, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Belgian Biotech Seed Investment to Produce Affordable Vaccines for Developing Countries

Meet the French Woman who started a Biotech to Save her Daughter from a Rare Disease

Wow, Europe’s leading CRISPR Biotech signs monster €2.29 Billion Deal

Dementia could bankrupt us all… The Biotech ‘A’ Team comes to the rescue!

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Financial Storm approaching? EU Biotechs start postponing their IPOs in London …

What Happened this Week? Ultimate Cancer Review, Biofuels, Microalgae

#Sorry: The World-leading Oncology Company fails in Phase III

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Biotech of the week: Genenta Biosciences, a Novel Gene Therapies from Italy

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

This €200M French Biotech uses Red blood Cells to Fight Leukemia & Pancreatic Cancer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!